MAZEMaze Therapeutics, Inc.

1. Aug 17, 2026On August 13, 2026, the Board of Directors (the “Board”) of Maze Therapeutics, Inc. (the “Company”) appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, in each case effective August 13, 2026 (the “Appointment Date”)Director or officer change · Form 8-K
2. Aug 11, 2026Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights.Earnings release · press release
3. May 22, 2026On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026.Director or officer change · Form 8-K
4. May 12, 2026Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights.Earnings release · press release
5. Apr 22, 2026On April 21, 2026, Maze Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC as sole underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 5,540,000 shares of its …Other event · Form 8-K
6. Mar 25, 2026On March 24, 2026, the Board of Directors (the “Board”) of the Company appointed Neil Kumar as a Class I director, effective March 27, 2026 (the “Appointment Date”)Earnings release · Form 8-K
7. Feb 4, 2026On February 4, 2026 (the “Closing Date”), Maze Therapeutics, Inc. (the “Company”) entered into that certain Loan and Security Agreement (the “Hercules Loan Agreement”), by and among the Company, as borrower, the lenders from time to time party thereto, and Hercules Capital, Inc., in its capacity as administrative …Material agreement entered · Form 8-K
8. Nov 6, 2025Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights.Earnings release · press release
9. Oct 6, 2025On October 3, 2025, the Board of Directors (the “Board”) of Maze Therapeutics, Inc. (the “Company”) appointed Hervé Hoppenot as a Class II director and as the Chairman of the Board, effective October 6, 2025 (the “Appointment Date”)Director or officer change · Form 8-K
10. Sep 11, 2025Securities Purchase Agreement On September 10, 2025, Maze Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.